{"entity":{"id":"alligator-bioscience","kind":"company","name":"Alligator Bioscience","aka":["Alligator Bioscience AB","STO:ATORX"],"tldr":"Alligator Bioscience is a Swedish biotech that makes antibodies to switch on the immune system inside tumours; its CD40 agonist mitazalimab, given with chemotherapy, shrank tumours in 42 per cent of people with untreated metastatic pancreatic cancer in a single-arm trial, which cannot show whether it improves survival.","summary":"Alligator Bioscience, based in Lund, develops tumour-directed immunotherapies from its FIND antibody library and RUBY bispecific format. Mitazalimab (ADC-1013), a CD40 agonist that primes dendritic cells and T cells, was tested with modified FOLFIRINOX in the single-arm phase 1b/2 OPTIMIZE-1 trial in untreated metastatic pancreatic cancer, which met its primary endpoint with a confirmed response rate of 42.1 per cent and reported median overall survival of 14.9 months; with no control group it cannot show whether mitazalimab improves survival, and the authors plan a randomised confirmatory trial. ATOR-4066 is a Neo-X-Prime bispecific against CD40 and CEACAM5.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.alligatorbioscience.com/"},{"label":"OPTIMIZE-1: mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer, single-arm phase 1b/2 (Lancet Oncol 2024)","url":"https://doi.org/10.1016/S1470-2045(24)00263-8"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["mitazalimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Lund","country":"SE","companyType":"biotech","website":"https://www.alligatorbioscience.com/","ticker":"STO:ATORX","founded":2001,"stage":"public","investors":[],"funding":[]},"route":"/companies/alligator-bioscience/","neighbours":{"drug":[{"id":"mitazalimab","kind":"drug","name":"Mitazalimab","route":"/drugs/mitazalimab/"}],"trial":[{"id":"nct04888312","kind":"trial","name":"Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients","route":"/trials/nct04888312/"}]}}